Thompson J S, Edney J A, Laughlin K
Dis Colon Rectum. 1986 Dec;29(12):873-7. doi: 10.1007/BF02555367.
Urine polyamine content is increased in patients with colorectal malignancy and may be a useful tumor marker in the management of these patients. Urinary excretion of putrescine and spermidine was measured preoperatively and in the first week postoperatively in nine patients with inflammatory bowel disease, eight with other benign colorectal disease, and 13 with colorectal cancer. Preoperative urine putrescine levels were elevated similarly in patients with inflammatory bowel disease and malignancy. Polyamine levels were increased in all three groups in the early postoperative period. Urinary polyamine excretion did not correlate with serum CEA levels, tumor volume, or stage of disease in patients with cancer. Because elevated levels of urinary polyamines are not specific for malignancy and do not correlate with other prognostic indicators, such measurements are unlikely to be useful in tumor detection and determining prognosis. Polyamine levels, however, may prove useful in monitoring response to therapy and detecting recurrences in individual patients.
结直肠癌患者尿液中的多胺含量会升高，其可能是这些患者治疗过程中一种有用的肿瘤标志物。对9例炎症性肠病患者、8例其他良性结直肠疾病患者和13例结直肠癌患者在术前及术后第一周测量了腐胺和亚精胺的尿排泄量。炎症性肠病患者和恶性肿瘤患者术前尿液腐胺水平同样升高。术后早期所有三组患者的多胺水平均升高。癌症患者的尿多胺排泄量与血清癌胚抗原水平、肿瘤体积或疾病分期无关。由于尿多胺水平升高并非恶性肿瘤所特有，且与其他预后指标无关，因此这类检测在肿瘤检测和判断预后方面不太可能有用。然而，多胺水平可能在监测个体患者的治疗反应和检测复发方面被证明是有用的。
